The Effectiveness of Topical Cerium Nitrate-Silver Sulfadiazine Application on Overall Outcome in Patients with Calciphylaxis.


Journal

Dermatology (Basel, Switzerland)
ISSN: 1421-9832
Titre abrégé: Dermatology
Pays: Switzerland
ID NLM: 9203244

Informations de publication

Date de publication:
2019
Historique:
received: 09 08 2018
accepted: 24 09 2018
pubmed: 4 1 2019
medline: 14 6 2019
entrez: 4 1 2019
Statut: ppublish

Résumé

Calciphylaxis (CPX) is a rare and life-threatening disease characterized by vascular calcification and development of painful and necrotizing skin lesions with a challenging management. Mechanisms of CPX are complex and include an imbalance between vascular calcification promoters and inhibitors, and frequently vitamin K deficiency. To describe the various presentations and identify predictive factors of death in patients with CPX. In this multicenter retrospective study, we included 71 CPX patients followed in South-West France (n = 26) and in French Polynesia (n = 45), and who all received sodium thiosulfate (25 g thrice weekly for a median of 61 days). Characteristics at presentation significantly differed between metropolitan and Polynesian French patients. Polynesians were less frequently on regular dialysis at the onset of CPX, had a higher incidence of diabetes mellitus and obesity, more disturbances of calcium-phosphorus metabolism, and received vitamin K antagonists less frequently than patients from South-West France. Despite intensive management, the 1-year mortality rate was 66% and median time to death was 200 days (IQR, 40; 514). The number of body areas involved (i.e., three: OR 2.70 [1.09; 6.65], p = 0.031; four: OR 8.79 [1.54; 50.29], p = 0.015) was the only predictive factor for death, whereas application of topical cerium nitrate-silver sulfadiazine was protective (OR 0.44 [0.20; 0.99], p = 0.046). Surgical debridement, hyperbaric oxygenation therapy, and geographical origin were not associated with overall outcomes. Cerium nitrate may lead to vascular decalcification and chelation of reactive oxygen species, and prevent infection. Cerium nitrate-silver sulfadiazine was associated with better outcomes and should be tested in a prospective comparative trial in CPX patients.

Sections du résumé

BACKGROUND BACKGROUND
Calciphylaxis (CPX) is a rare and life-threatening disease characterized by vascular calcification and development of painful and necrotizing skin lesions with a challenging management. Mechanisms of CPX are complex and include an imbalance between vascular calcification promoters and inhibitors, and frequently vitamin K deficiency.
OBJECTIVES OBJECTIVE
To describe the various presentations and identify predictive factors of death in patients with CPX.
METHODS METHODS
In this multicenter retrospective study, we included 71 CPX patients followed in South-West France (n = 26) and in French Polynesia (n = 45), and who all received sodium thiosulfate (25 g thrice weekly for a median of 61 days).
RESULTS RESULTS
Characteristics at presentation significantly differed between metropolitan and Polynesian French patients. Polynesians were less frequently on regular dialysis at the onset of CPX, had a higher incidence of diabetes mellitus and obesity, more disturbances of calcium-phosphorus metabolism, and received vitamin K antagonists less frequently than patients from South-West France. Despite intensive management, the 1-year mortality rate was 66% and median time to death was 200 days (IQR, 40; 514). The number of body areas involved (i.e., three: OR 2.70 [1.09; 6.65], p = 0.031; four: OR 8.79 [1.54; 50.29], p = 0.015) was the only predictive factor for death, whereas application of topical cerium nitrate-silver sulfadiazine was protective (OR 0.44 [0.20; 0.99], p = 0.046). Surgical debridement, hyperbaric oxygenation therapy, and geographical origin were not associated with overall outcomes.
CONCLUSIONS CONCLUSIONS
Cerium nitrate may lead to vascular decalcification and chelation of reactive oxygen species, and prevent infection. Cerium nitrate-silver sulfadiazine was associated with better outcomes and should be tested in a prospective comparative trial in CPX patients.

Identifiants

pubmed: 30605905
pii: 000493975
doi: 10.1159/000493975
doi:

Substances chimiques

Anti-Infective Agents, Local 0
Chelating Agents 0
Drug Combinations 0
Thiosulfates 0
cerium nitrate 17309-53-4
Cerium 30K4522N6T
sodium thiosulfate HX1032V43M
Silver Sulfadiazine W46JY43EJR

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

120-129

Informations de copyright

© 2019 S. Karger AG, Basel.

Auteurs

Amandine Darres (A)

Department of Nephrology and Organ Transplantation, Center for Rare Renal Disease, University Hospital of Toulouse, Toulouse, France.

Ronan Delaval (R)

Department of Nephrology, Taaone Hospital, Papeete, French Polynesia.

Alain Fournier (A)

Department of Nephrology, Taaone Hospital, Papeete, French Polynesia.

Emilie Tournier (E)

Department of Pathology, Cancer University Institute of Toulouse, Toulouse, France.

Olivier Cointault (O)

Department of Nephrology and Organ Transplantation, Center for Rare Renal Disease, University Hospital of Toulouse, Toulouse, France.

Francoise Moussion (F)

Department of Nephrology, Saint-Exupery Clinic, Toulouse, France.

Dominique Chauveau (D)

Department of Nephrology and Organ Transplantation, Center for Rare Renal Disease, University Hospital of Toulouse, Toulouse, France.

Bruno Seigneuric (B)

Department of Nephrology and Organ Transplantation, Center for Rare Renal Disease, University Hospital of Toulouse, Toulouse, France.

Catherine Lumbroso (C)

Department of Nephrology, Taaone Hospital, Papeete, French Polynesia.

Nassim Kamar (N)

Department of Nephrology and Organ Transplantation, Center for Rare Renal Disease, University Hospital of Toulouse, Toulouse, France.

David Ribes (D)

Department of Nephrology and Organ Transplantation, Center for Rare Renal Disease, University Hospital of Toulouse, Toulouse, France.

Sylvie Leou (S)

Department of Nephrology, Taaone Hospital, Papeete, French Polynesia.

Antoine Huart (A)

Department of Nephrology and Organ Transplantation, Center for Rare Renal Disease, University Hospital of Toulouse, Toulouse, France.

Pascale Testevuide (P)

Department of Nephrology, Taaone Hospital, Papeete, French Polynesia.

Stanislas Faguer (S)

Department of Nephrology and Organ Transplantation, Center for Rare Renal Disease, University Hospital of Toulouse, Toulouse, France, Stanislas.faguer@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH